Novo Nordisk announced Thursday that it has entered an exclusive development and license agreement for $70 million with Ventus Therapeutics for its NLRP3 inhibitor program. As part of the transaction, ...

Since the beginning of our partnership with Ventus, we have seen additional evidence for the broad range of opportunities addressable by targeting NLRP3,” said Karin Conde-Knape, senior vice president ...

The Novo Nordisk ... from Novo Nordisk, we are in a stronger position to advance HT-6184 toward clinical development.” Halia’s HT-6184 is a first-in-class NEK7/NLRP3 inflammasome inhibitor ...

diabetes and neurodegenerative conditions have all been linked to excessive NLRP3 activity, sparking interest from companies like Novo Nordisk in targeting it. In the case of obesity, researchers ...